Business Context and Reporting Period
Company: AspenBio Pharma, Inc. (Note: Request metadata listed "Riot Platforms," but the filing text is for AspenBio Pharma, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: AspenBio is a biopharmaceutical company focused on developing diagnostic tests (specifically the AppyScore appendicitis test) and recombinant single-chain animal health products (BoviPure LH and FSH) in collaboration with Novartis Animal Health.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Revenue (Sales) | $142,133 | $82,147 |
| Gross Profit | $76,567 | $(34,079) |
| Operating Loss | $(3,835,320) | $(2,756,161) |
| Net Loss | $(3,871,436) | $(2,720,758) |
| Net Loss Per Share (Basic/Diluted) | $(0.10) | $(0.09) |
| Cash and Cash Equivalents (End of Period) | $10,769,909 | $13,466,355 |
| Working Capital | $8,012,489 | N/A |
| Total Debt (Notes & Obligations) | $2,735,375 | $2,762,835 |
Cash Flow Summary (Q1 2010):
- Operating Activities: $(3,135,879) used
- Investing Activities: $394,443 provided
- Financing Activities: $144,568 provided
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 73% to $142,133, driven by the timing of customer orders. The company suspended antigen production to focus resources on appendicitis and animal product development.
- Gross Margin Improvement: The company moved from a gross loss of 42% in Q1 2009 to a gross profit margin of 54% in Q1 2010. This was due to inventory write-downs in late 2009 and the exclusion of fixed overhead costs associated with suspended antigen production.
- Operating Expenses: Total operating expenses rose 43% to $3.93 million.
- Selling, General & Administrative (SG&A): Increased 43% to $1.88 million, primarily due to hiring for clinical trials (AppyScore) and increased stock-based compensation ($594,752 vs. $388,127).
- Research & Development (R&D): Increased 44% to $2.04 million, driven by clinical trial costs, FDA submission activities, and expanded staff.
- Interest Income: Decreased significantly from $76,294 to $12,309 due to lower cash balances and reduced investment returns.
Guidance, Outlook, and Risks
Capital Resources & Liquidity:
- The company reported a net loss of $3.87 million for the quarter.
- As of March 31, 2010, working capital was approximately $8.0 million.
- Subsequent Financing: On May 5, 2010, the company closed a registered direct offering of units (stock and warrants) raising approximately $10.0 million in gross proceeds (approx. $9.1 million net). Management believes this, combined with current cash, is sufficient for near-term operations.
Outlook & Strategy:
- Primary focus remains on advancing the AppyScore appendicitis test through FDA clearance and developing single-chain animal hormone products with Novartis.
- Capital expenditures for the remainder of 2010 are estimated at $200,000 to $400,000.
Risks & Contingencies:
- Product Development Risk: Failure to achieve FDA clearance for AppyScore could result in impairment of incurred costs and a need to rely on other revenue streams.
- Customer Concentration: Two customers accounted for 81% of accounts receivable as of March 31, 2010.
- Debt Obligations: The company has a mortgage facility with a balloon payment of approximately $1.6 million due in July 2013.
Investor Verification Checklist
- Financing Closure: Verify the final net proceeds from the May 5, 2010 registered direct offering and the impact on share count (2.4 million shares issued).
- FDA Status: Monitor the progress of the AppyScore 510(k) submission and clinical trial results, as this is the primary driver for future revenue.
- Novartis Agreement: Confirm the status of the conditions required to secure the remaining 50% of the $2.0 million upfront payment from the Novartis license agreement.
- Burn Rate: Assess the sustainability of the current operating loss (~$3.9M/quarter) against the new cash infusion to determine runway.
- Debt Maturity: Review the company's plan for the $1.6 million mortgage balloon payment due in 2013.